Nutritional support in hospitalised patients with diabetes and risk for malnutrition: a secondary analysis of an investigator-initiated, Swiss, randomised controlled multicentre trial

被引:0
|
作者
Keller, Bettina [1 ]
Wunderle, Carla [1 ]
Tribolet, Pascal [1 ]
Stanga, Zeno [2 ]
Kaegi-Braun, Nina [3 ]
Mueller, Beat [4 ,5 ]
Schuetz, Philipp [1 ]
机构
[1] Kantonsspital Aarau AG, Aarau, Switzerland
[2] Univ Bern, Fac Med, Bern, Switzerland
[3] Karolinska Inst, Stockholm, Sweden
[4] Univ Basel, Med Fac, Dept Clin Res, Basel, Switzerland
[5] Cantonal Hosp Aarau, Med Univ Dept, Clin Endocrinol, Aarau, Aargau, Switzerland
来源
BMJ OPEN | 2024年 / 14卷 / 08期
基金
瑞士国家科学基金会;
关键词
Nutritional support; NUTRITION & DIETETICS; Randomized Controlled Trial; DIABETES & ENDOCRINOLOGY; MEDICAL INPATIENTS; CLINICAL-OUTCOMES; MELLITUS; PREVALENCE; INFECTION; FORMULAS; COVID-19; PEOPLE; OLDER;
D O I
10.1136/bmjopen-2024-084754
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The main objective of this study was to investigate the effects of nutritional support on mortality in hospitalised patients with diabetes and nutritional risk participating in the Effect of early nutritional support on Frailty, Functional Outcomes, and Recovery of malnourished medical inpatients Trial (EFFORT) trial. Design Secondary analysis of a Swiss-wide multicentre, randomised controlled trial. Participants Patients with diabetes and risk for malnutrition. Interventions Individualised nutritional support versus usual care. Primary outcome measure 30-day all-cause mortality. Results Of the 2028 patients included in the original trial, 445 patients were diagnosed with diabetes and included in this analysis. In terms of efficacy of nutritional therapy, there was a 25% lower risk for mortality in patients with diabetes receiving nutritional support compared with controls (7% vs 10%, adjusted HR 0.75 (95% CI 0.39 to 1.43)), a finding that was not statistically significant but similar to the overall trial effects with no evidence of interaction (p=0.92). Regarding safety of nutritional therapy, there was no increase in diabetes-specific complications associated with nutritional support, particularly there was no increase in risk for hyperglycaemia (adjusted OR 0.97, 95% CI 0.56 to 1.67 p=0.90). Conclusion Patients with diabetes and malnutrition in the hospital setting have a particularly high risk for adverse outcomes and mortality. Individualised nutritional support reduced mortality in this secondary analysis of a randomized trial, but this effect was not significant calling for further large-scale trials in this vhighly ulnerable patient population.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Admission serum albumin concentrations and response to nutritional therapy in hospitalised patients at malnutrition risk: Secondary analysis of a randomised clinical trial
    Bretscher, Celine
    Boesiger, Fabienne
    Kaegi-Braun, Nina
    Hersberger, Lara
    Lobo, Dileep N.
    Evans, David C.
    Tribolet, Pascal
    Gomes, Filomena
    Hoess, Claus
    Pavlicek, Vojtech
    Bilz, Stefan
    Sigrist, Sarah
    Brandle, Michael
    Henzen, Christoph
    Thomann, Robert
    Rutishauser, Jonas
    Aujesky, Drahomir
    Rodondi, Nicolas
    Donze, Jacques
    Stanga, Zeno
    Mueller, Beat
    Schuetz, Philipp
    ECLINICALMEDICINE, 2022, 45
  • [2] Efficacy of Alkaline Phosphatase in Critically Ill Patients with COVID-19: A Multicentre Investigator-Initiated Double-Blind Randomised Placebo-Controlled Trial
    Pijpe, Anouk
    Papendorp, Stephan G.
    van der Heijden, Joost W.
    Vermin, Ben
    Ertugrul, Iris
    Ritt, Michael W. J.
    Stessel, Bjorn
    Callebaut, Ina
    Beishuizen, Albertus
    Vlig, Marcel
    Jimmink, Joost
    Huijgen, Henk J.
    van Zuijlen, Paul P. M.
    Middelkoop, Esther
    de Jong, Evelien
    BIOMEDICINES, 2024, 12 (04)
  • [3] NSAIDs in sciatica (NIS): study protocol for an investigator-initiated multicentre, randomized placebo-controlled trial of naproxen in patients with sciatica
    Grovle, Lars
    Hasvik, Eivind
    Holst, Rene
    Haugen, Anne Julsrud
    TRIALS, 2022, 23 (01)
  • [4] NSAIDs in sciatica (NIS): study protocol for an investigator-initiated multicentre, randomized placebo-controlled trial of naproxen in patients with sciatica
    Lars Grøvle
    Eivind Hasvik
    Rene Holst
    Anne Julsrud Haugen
    Trials, 23
  • [5] Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, randomised, placebo-controlled trial
    Idorn, T.
    Knop, F. K.
    Jorgensen, M. B.
    Jensen, T.
    Resuli, M.
    Hansen, P. M.
    Christensen, K. B.
    Holst, J. J.
    Hornum, M.
    Feldt-Rasmussen, B.
    DIABETOLOGIA, 2014, 57 : S370 - S371
  • [6] An investigator-initiated phase II trial of tirabrutinib in patients with relapsed or refractory secondary CNS lymphoma
    Munakata, W.
    Goto, H.
    Fukuhara, N.
    Nagai, H.
    Arima, H.
    Kato, K.
    Kurishita, K.
    Shuda, Y.
    Isomura, R.
    Ando, Y.
    Iwaki, N.
    Sadachi, R.
    Okita, N.
    Izutsu, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1360 - S1360
  • [7] Once versus twice daily mesalazine to induce remission in paediatric ulcerative colitis: an investigator-initiated randomised controlled trial
    Turner, D.
    Yerushalmi, B.
    Kori, M.
    Broide, E.
    Mozer-Glassberg, Y.
    Shaoul, R.
    Kolho, K-L
    Shteyer, E.
    Shamaly, H.
    Ledder, O.
    Cohen, S.
    Peleg, S.
    On, A.
    Levine, A.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S416 - S416
  • [8] Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
    Kedor, Claudia
    Detert, Jacqueline
    Rau, Rolf
    Wassenberg, Siegfried
    Listing, Joachim
    Klaus, Pascal
    Braun, Tanja
    Hermann, Walter
    Weiner, Stefan Markus
    Buttgereit, Frank
    Burmester, Gerd R.
    RMD OPEN, 2021, 7 (02):
  • [9] EFFICACY AND SAFETY OF ADALIMUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS - AN INVESTIGATOR-INITIATED RANDOMIZED PLACEBO-CONTROLLED TRIAL
    Krabbe, S.
    Ostergaard, M.
    Sorensen, I. J.
    Jensen, B.
    Madsen, O. R.
    Eng, G. P.
    Asmussen, K. H.
    Moller, J.
    Balding, L.
    Pedersen, S. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1131 - 1132
  • [10] Randomized Controlled Trial of Remimazolam Compared with Placebo in Japanese Patients Undergoing Colonoscopy: A Phase III, Investigator-Initiated Trial
    Ichijima, Ryoji
    Ikehara, Hisatomo
    Ono, Hiroyuki
    Hotta, Kinichi
    Yamaguchi, Daisuke
    Esaki, Mitsuru
    Minoda, Yosuke
    Nagata, Yasuhiko
    Ogura, Kanako
    Kiriyama, Shinsuke
    Sumiyoshi, Tetsuya
    Kanmura, Yuichi
    DIGESTION, 2024, 105 (06) : 448 - 456